The efficacy and safety of onabotulinumtoxinA (BOTOX®, Allergan, Dublin, Ireland) in the treatment of overactive bladder syndrome (OAB) has been established in various studies and is recommended as the third-line therapy. Despite this, numerous patients who could benefit from onabotulinumtoxinA for refractory OAB are not receiving it. Patients and/or physicians have concerns and misunderstandings regarding potential post void residual (PVR).
Latest articles
All articles
